Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-05-05 DOI:10.1080/14796694.2025.2496131

Christophe Le Tourneau, Zoltán Takácsi-Nagy, Sandra Nuyts, Sébastien Thureau, Feng Liu, Caroline Hoffmann, Trevor G Hackman, Maria Lesnik, Anaïs Debard, Laetitia Finzi, Kiran Devisetty, Omar I Vivar, Leonard A Farber, France Nguyen, Xavier Liem, Eteri Natelauri, Amanda Psyrri, Martin Burian, Jinming Yu, Sue S Yom

引用次数: 0

Abstract

Clinical trial registration: https://clinicaltrials.gov identifier is NCT04892173; EudraCT Number: 2021-002163-22.

查看原文本刊更多论文

nanory -312: NBTXR3 +放疗±西妥昔单抗治疗老年铂不合格局部晚期HNSCC的III期研究

临床试验注册：https://clinicaltrials.gov标识符：NCT04892173；草案编号：2021-002163-22。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.